1·Patients who are H. pylori positive are also at high risk, as are those who take Nsaids while also taking blood thinners (such as warfarin or antiplatelet drugs) or steroids.
幽门螺杆菌阳性的病人也是要关注的对象，还有那些服用非甾体消炎药的同时还服用血液稀释剂(例如华法令阻凝剂或者抗血小板药物)或甾类化合物的人。
2·But these antiplatelet drugs also increase the risk of bleeding, including upper GI bleeding.
但是这些抗血小板药物也增加出血的风险，包括上消化道出血。
3·The FDA also recommends prolonged dual antiplatelet therapy for at least a year following the intervention.
FDA也推荐介入治疗后至少延长一年对病人进行双重抗血小板治疗。
4·And there's consensus that the increased ischemic events are related to insufficient antiplatelet and antithrombotic therapy.
现在专家的一致意见认为，这可能是由于抗血小板和抗血栓治疗不足所引起的。
5·There is no evidence that antiplatelet agents reduce atherosclerotic risk in patients with HF.
没有任何证据表明，抗血小板制剂降低心衰患者动脉粥样硬化的危险。